Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension

References

• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019:53(1).
   Web of Science ®Google Scholar
• Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Apitz C, Grunig E, et al. Targeted therapy of pulmonary arterial hypertension: updated recommendations from the cologne consensus conference 2018. Int J Cardiol. 2018;272S:37–45.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115(1):165–175.
   PubMed Web of Science ®Google Scholar
• Marsh LM, Jandl K, Grünig G, et al. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51(1):1701214.
   PubMed Web of Science ®Google Scholar
• Goldenberg NM, Rabinovitch M, Steinberg BE. Inflammatory basis of pulmonary arterial hypertension: implications for perioperative and critical care medicine. Anesthesiology. 2019;131(4):898–907.
   PubMed Web of Science ®Google Scholar
• Oh S, Jang AY, Chae S, et al. Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension. Sci Rep. 2021;11(1):1–15.
   PubMed Web of Science ®Google Scholar
• De Mendonca L, Felix NS, Blanco NG, et al. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther. 2017;8(1):1–15.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Rajkumar R, Konishi K, Richards TJ, et al. Genomewide rna expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2010;298(4):H1235–H1248.
   PubMed Web of Science ®Google Scholar
• Mura M, Cecchini MJ, Joseph M, et al. Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. Respirology. 2019;24(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheumatism. 2011;63(3):783–794.
   PubMed Web of Science ®Google Scholar
• Poh LNF, Cheadle C, Berger AE, et al. Erythroid-specific transcriptional changes in pbmcs from pulmonary hypertension patients. PLoS ONE. 2012;7(4):e34951.
   Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. Clusterprofiler: an r package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Carlson M, Falcon S, Pages H, et al. org. Hs. eg. db: Genome wide annotation for Human. R package version, 2017, 3(1)
   Google Scholar
• Ginestet C. Ggplot2: elegant graphics for data analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society). 2011;174(1):245–246.
   Web of Science ®Google Scholar
• Mering C. String: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261.
   PubMed Web of Science ®Google Scholar
• Hu K. Become competent within one day in generating boxplots and violin plots for a novice without prior r experience. Methods and Protocols. 2020;3(4):64.
   PubMedGoogle Scholar
• Bhattacharya S, Andorf S, Gomes L, et al. Immport: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–239.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. Drugbank 5.0: a major update to the drugbank database for 2018. Nucleic Acids Res. 2018;46:D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Patil I. Ggstatsplot: ‘Ggplot2ʹ based plots with statistical details. 2018.
   Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. 2015 esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Dorfmuller P. Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med. 2013;34(5):551–559.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1).
   Google Scholar
• Breitling S, Hui Z, Zabini D, et al. The mast cell–b cell axis in lung vascular remodeling and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L710–L721.
   PubMed Web of Science ®Google Scholar
• Klouda T, Yuan K. Inflammation in pulmonary arterial hypertension. Lung Inflammation in Health and Disease, Volume I. 2021;1303:351.
   Google Scholar
• Koudstaal T, Boomars KA, Kool M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an immunological perspective. J Clin Med. 2020;9(2):9.
   Web of Science ®Google Scholar
• Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(9):897–908.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J. 2012;40:515–517.
   Web of Science ®Google Scholar
• Tuder RM, Groves BM, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275–285.
   PubMed Web of Science ®Google Scholar
• Ulrich S, Taraseviciene-Stewart L, Huber LC, et al. Peripheral blood b lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different rna pattern compared with healthy controls: a cross sectional study. Respir Res. 2008;9:9.
   PubMed Web of Science ®Google Scholar
• Li C, Liu P, Song R, et al. Immune cells and autoantibodies in pulmonary arterial hypertension. Acta Biochim Biophys Sin (Shanghai). 2017;49(12):1047–1057.
   PubMed Web of Science ®Google Scholar
• Liu XD, Guo SY, Yang LL, et al. Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension. J Thorac Dis. 2014;6(5):497–502.
   PubMed Web of Science ®Google Scholar
• Tamby MC. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J. 2006;28(4):799–807.
   PubMed Web of Science ®Google Scholar
• Nicolls MR. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005;26(6):1110–1118.
   PubMed Web of Science ®Google Scholar
• Loh TY, Hsiao JL, Shi VY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020;13:109–114.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF Jr, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Maher TM, Costabel U, Glassberg MK, et al. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(2).
   Google Scholar
• Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2009;181(2):158–167.
   PubMed Web of Science ®Google Scholar
• Sagar D, Vandana P. Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a qbd approach. Drug Delivery & Translational Research. 2019;9(5):980–996.
   Web of Science ®Google Scholar
• Yu X, Zhao X, Zhang J, et al. Dacomitinib, a new pan-egfr inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension. Eur J Pharmacol. 2019;850:97–108.
   PubMed Web of Science ®Google Scholar
• Gliga S, Orth HM, Lübke N, et al. Multicentric castleman’s disease in hiv patients: a single-center cohort diagnosed from 2008 to 2018. Infection. 2021;1–7.
   Web of Science ®Google Scholar
• Gritti G, Raimondi F, Bottazzi B, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe covid-19. Leukemia. 2021;35(1):1–5.
   PubMed Web of Science ®Google Scholar
• Albiach L, Agüero D, Ambrosioni J, et al. Tocilizumab reduces the risk of icu admission and mortality in patients with sars-cov-2 infection.
   Google Scholar
• Hernandez-Sanchez J, Harlow L, Church C, et al. Express: clinical trial protocol for transform-uk: a therapeutic open label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ. 2017;8(1):204589321773582.
   Web of Science ®Google Scholar
• Florentin J, Coppin E, Vasamsetti SB, et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes. J Immunol. 2018;200(10):3612–3625.
   PubMed Web of Science ®Google Scholar
• Florentin J, Zhao J, Tai -Y-Y, et al. Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension. Cell Mol Immunol. 2021;18(2):374–384.
   PubMed Web of Science ®Google Scholar
• Amsellem V, Abid S, Poupel L, et al. Roles for the cx3cl1/cx3cr1 and ccl2/ccr2 chemokine systems in hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2017;56(5):597.
   PubMed Web of Science ®Google Scholar